Abiomed will report data from its ST segment elevation myocardial infarction Door to Unloading study on November 11, Jefferies analyst Raj Denhoy tells investors in a research note. The analyst says that while only designed as a feasibility study with 50 patients, the rationale for the study and results from previous studies suggest it could show more than just equivalence. Any positive result would add support to the idea that Abiomed is well on its way to opening up a market of 200,000-300,000 patients per year worth $4B-$6B in the U.S. alone, says Denhoy. This would essentially double the addressable market for Impella, the analyst adds. He keeps a Buy rating on Abiomed with a $400 price target.